Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Sell
25
ARCB Quote, Financials, Valuation and Earnings
Last price:
$71.68
Seasonality move
:
-0.57%
Day range:
$68.83 - $71.93
52-week range:
$68.83 - $153.61
Dividend yield:
0.67%
P/E ratio:
9.78x
P/S ratio:
0.41x
P/B ratio:
1.26x
Volume:
487.7K
Avg. volume:
358.1K
1-year change:
-48.12%
Market cap:
$1.7B
Revenue:
$4.2B
EPS (TTM):
$7.33
Analysts' Opinion
-
Consensus RatingArcBest has received a consensus rating of Hold. The company's average rating is a Hold based on 5 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $105.92, ArcBest has an estimated upside of 47.77% from its current price of $71.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $73.00 representing 100% downside risk from its current price of $71.68.
Fair Value
-
According to the consensus of 12 analysts, ArcBest has 47.77% upside to fair value with a price target of $105.92 per share.
ARCB vs. S&P 500
-
Over the past 5 trading days, ArcBest has underperformed the S&P 500 by -2.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ArcBest does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ArcBest revenues have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter ArcBest reported revenues of $1B.
Earnings Growth
-
ArcBest earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter ArcBest reported earnings per share of $1.24.
Enterprise value:
1.7B
EV / Invested capital:
1.12x
Price / LTM sales:
0.41x
EV / EBIT:
7.43x
EV / Revenue:
0.40x
PEG ratio (5yr expected):
1.21x
EV / Free cash flow:
36.89x
Price / Operating cash flow:
37.01x
Enterprise value / EBITDA:
4.49x
Gross Profit (TTM):
$350M
Return On Assets:
7.19%
Net Income Margin (TTM):
4.16%
Return On Equity:
13.77%
Return On Invested Capital:
11.86%
Operating Margin:
3.03%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $5B | $4.4B | $4.2B | $1.1B | $1B | |
| Gross Profit | $573.5M | $378.5M | $350M | $114.8M | $82.8M | |
| Operating Income | $412.8M | $183.7M | $155.9M | $58M | $30.4M | |
| EBITDA | $536.1M | $341.7M | $376.8M | $107.5M | $79.2M | |
| Diluted EPS | $11.66 | $7.91 | $7.33 | $2.01 | $1.24 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $758.2M | $776.1M | $989.8M | $884.8M | $675.6M | |
| Total Assets | $1.8B | $2.1B | $2.5B | $2.5B | $2.4B | |
| Current Liabilities | $506.5M | $702.7M | $768.5M | $701.6M | $666M | |
| Total Liabilities | $950.4M | $1.2B | $1.3B | $1.2B | $1.1B | |
| Total Equity | $828.6M | $929.1M | $1.2B | $1.2B | $1.3B | |
| Total Debt | $284.2M | $225.5M | $264.6M | $228.9M | $189.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $470.8M | $322.2M | $285.8M | $127.4M | $56.8M | |
| Cash From Investing | -$261.1M | -$21.7M | -$187.3M | -$69.6M | -$37.8M | |
| Cash From Financing | -$128M | -$196.6M | -$233.3M | -$47.1M | -$42M | |
| Free Cash Flow | $305.3M | $90.2M | $45.8M | $34.6M | -$926K | |
ARCB
Sector
Market Cap
$1.7B
$618.1M
Price % of 52-Week High
46.67%
74.1%
Dividend Yield
0.67%
0%
Shareholder Yield
4.47%
2.42%
1-Year Price Total Return
-48.12%
-6.88%
Beta (5-Year)
1.546
0.889
Dividend yield:
0.67%
Annualized payout:
$0.48
Payout ratio:
6.49%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$72.84
200-day SMA
Sell
Level
$102.59
Bollinger Bands (100)
Sell
Level
84.41 - 109.89
Chaikin Money Flow
Buy
Level
41.6M
20-day SMA
Sell
Level
$76.38
Relative Strength Index (RSI14)
Sell
Level
29.12
ADX Line
Sell
Level
39.83
Williams %R
Neutral
Level
-65.3285
50-day SMA
Sell
Level
$88.27
MACD (12, 26)
Sell
Level
-4.98
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
48.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.03)
Buy
CA Score
(Annual)
Level (0.7139)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.5806)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers’ supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
Stock Forecast FAQ
In the current month, ARCB has received 5 Buy ratings 7 Hold ratings, and 0 Sell ratings. The ARCB average analyst price target in the past 3 months is $105.92.
-
Where Will ArcBest Stock Be In 1 Year?
According to analysts, the consensus estimate is that ArcBest share price will rise to $105.92 per share over the next 12 months.
-
What Do Analysts Say About ArcBest?
Analysts are divided on their view about ArcBest share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ArcBest is a Sell and believe this share price will drop from its current level to $73.00.
-
What Is ArcBest's Price Target?
The price target for ArcBest over the next 1-year time period is forecast to be $105.92 according to 12 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is ARCB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ArcBest is a Hold. 7 of 12 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ARCB?
You can purchase shares of ArcBest via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ArcBest shares.
-
What Is The ArcBest Share Price Today?
ArcBest was last trading at $71.68 per share. This represents the most recent stock quote for ArcBest. Yesterday, ArcBest closed at $71.68 per share.
-
How To Buy ArcBest Stock Online?
In order to purchase ArcBest stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
